Novonesis (Novozymes) B (LTS:0Q4U) Total Stockholders Equity : kr82,125 Mil (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Novonesis (Novozymes) B Total Stockholders Equity?

Novonesis (Novozymes) B's Total Stockholders Equity for the quarter that ended in Jun. 2024 was kr82,125 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Novonesis (Novozymes) B's Book Value per Share for the quarter that ended in Jun. 2024 was kr176.86. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Novonesis (Novozymes) B's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.18.

Novonesis (Novozymes) B Total Stockholders Equity Historical Data

The historical data trend for Novonesis (Novozymes) B's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Total Stockholders Equity Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

11,465.21

11,230.37

11,825.22

13,815.83

13,993.50

Novonesis (Novozymes) B Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															12,869.02	13,382.59	14,452.50	13,993.50	82,124.72

Novonesis (Novozymes) B (LTS:0Q4U) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Novonesis (Novozymes) B's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(82124.723	-	0)	/	464.356
	=	176.86

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Novonesis (Novozymes) B's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6841.799	+	8004.614)	/	82124.723
	=	0.18

Novonesis (Novozymes) B Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (LTS:0Q4U) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NVZMF:USA NSISBc:UK NSIS B:Denmark NZM2:Germany

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines